Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer
A phase 2 trial of gemcitabine, cisplatin, oxaliplatin and other drugs in gallbladder cancer and other biliary tract cancers, run by First Affiliated Hospital of Zhejiang University, now recruiting.
Overview
Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer is a phase 2, randomised interventional study registered as NCT07025174 by First Affiliated Hospital of Zhejiang University, with a registry enrolment figure of 60 participants, started 2025-06-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib, Oxaliplatin + 5-Fluorouracil/Leucovorin. Conditions listed: Bile Duct Carcinoma, Gall Bladder Cancer, Biliary Tract Cancer, Cholangiocarcinoma. Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
Shares Leucovorin (folinic acid), Oxaliplatin, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma and the tag gallbladder-deep-dive.
- TrialQL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Shares Oxaliplatin, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialPrecision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study
Shares Oxaliplatin, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialQL1706（Iparomlimab/Tuvonralimab) Combined With Gemcitabine and Cisplatin as First-Line Treatment for PD-L1-Positive Biliary Tract Cancer
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialPembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Shares Oxaliplatin, Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups) and the tag gallbladder-deep-dive.
- TrialAnlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
Shares Anlotinib, Leucovorin (folinic acid), Oxaliplatin, Fluorouracil (5-FU) and the tag gallbladder-deep-dive.
- TrialPerioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.
- TrialChidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma
Shares Extrahepatic cholangiocarcinoma (perihilar and distal), Intrahepatic cholangiocarcinoma, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents and the tag gallbladder-deep-dive.